The first examples of(arene)Os(II)curcuminoid derivatives have been prepared and characterized.The neutral complexes[(p-cym)Os(curc)Cl](1)and[(p-cym)Os(bdcurc)Cl](2),together with the cationic derivatives[(p-cym)Os(cu...The first examples of(arene)Os(II)curcuminoid derivatives have been prepared and characterized.The neutral complexes[(p-cym)Os(curc)Cl](1)and[(p-cym)Os(bdcurc)Cl](2),together with the cationic derivatives[(p-cym)Os(curc)(PTA)][SO_(3)CF_(3)](3)and[(p-cym)Os(bdcurc)(PTA)][SO_(3)CF_(3)](4)(PTA=1,3,5-triaza-7-phosphaadamantane)were characterized by NMR spectroscopy and ESI mass spectrometry,and the crystal structure of 1 was determined by X-ray diffraction analysis.The cytotoxicity of the complexes was evaluated in vitro against human ovarian carcinoma cells(A2780 and A2780cisR),as well as against non-tumorous Human Embryonic Kidney cells(HEK293).Binding of the complexes to potential pharmacological targets and serum carriers was also explored.展开更多
基金supported by the University of Camerino(Fondo di Ateneo per la Ricerca 2018).
文摘The first examples of(arene)Os(II)curcuminoid derivatives have been prepared and characterized.The neutral complexes[(p-cym)Os(curc)Cl](1)and[(p-cym)Os(bdcurc)Cl](2),together with the cationic derivatives[(p-cym)Os(curc)(PTA)][SO_(3)CF_(3)](3)and[(p-cym)Os(bdcurc)(PTA)][SO_(3)CF_(3)](4)(PTA=1,3,5-triaza-7-phosphaadamantane)were characterized by NMR spectroscopy and ESI mass spectrometry,and the crystal structure of 1 was determined by X-ray diffraction analysis.The cytotoxicity of the complexes was evaluated in vitro against human ovarian carcinoma cells(A2780 and A2780cisR),as well as against non-tumorous Human Embryonic Kidney cells(HEK293).Binding of the complexes to potential pharmacological targets and serum carriers was also explored.
